64Cu-LLP2A for Imaging Multiple Myeloma

Summary

The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR). The investigators suggest that 64Cu-LLP2A will allow for an accurate molecular imaging of MM lesions, which will have an important impact on early stage disease detection and in the long term on the initiation and choice of therapy in these patients.

Timeline

Start

2018-11-20

Primary completion

2021-10-01

Completion

2021-10-01

Outcome

Outcome not reported

Stopped: “Drug formulation changed, opening new trial”

Drugs

Indications